Five-Membered-Fused Six-Membered Compounds for Dual-Function IRAK4 Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IRAK4 inhibitors primarily target the kinase function of IRAK4, neglecting its scaffolding function, which may limit therapeutic efficacy in autoimmune diseases and cancer.
Innovation Solution
Development of a five-membered-fused six-membered compound that inhibits or degrades IRAK4, addressing both kinase and scaffolding functions to enhance therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If current IRAK4 inhibitors targeting only kinase function are used, then development simplicity is maintained, but therapeutic efficacy is limited
Solution Approach 1:
The patent applies multi-functionality by designing PROTAC molecules that simultaneously target both the kinase function and scaffolding function of IRAK4. The compound contains a IRAK4 binding moiety that can engage with multiple functional domains of the target protein, enabling dual inhibition through a single agent rather than requiring separate inhibitors for each function.
Solution Approach 2:
The PROTAC molecule employs a nested structure where a IRAK4 binding moiety is integrated within a larger degrader framework. The binding moiety is nested within the PROTAC architecture, allowing it to specifically recognize IRAK4 while the outer structure facilitates ubiquitin ligase recruitment and protein degradation, creating a hierarchical functional organization.
2Ease of manufacture
If IRAK4 scaffolding function is neglected, then current inhibitor development is simplified, but broader efficacy in autoimmune diseases and cancer is compromised
Solution Approach 1:
The PROTAC compound achieves universality by being designed to interfere with multiple functional aspects of IRAK4 (both kinase and scaffolding functions), making it applicable to a broader range of diseases driven by IRAK4 activity, including various autoimmune conditions and cancer types, rather than being limited to specific pathways.
Solution Approach 2:
The patent employs parameter changes by modifying the molecular architecture from simple kinase inhibitors to complex PROTAC molecules with altered binding characteristics. This structural parameter change enables the compound to interact with different functional domains of IRAK4, expanding its therapeutic versatility across multiple disease indications.
Data Source
AI summary
A five-membered-fused six-membered compound, a preparation method, a pharmaceutical composition, and the use. The penta-fused hexa-heterocyclic compound is a compound represented by formula (II) or (III). The compound has an inhibition or/and degradation effect on IRAK4.